spacer
home > ict > autumn 2009 > asean all-stars
PUBLICATIONS
International Clinical Trials

ASEAN All-Stars

 

The clinical trial landscape has changed dramatically over the past decade. Whereas at the turn of the century, almost all clinical trial research was carried out in the US and western Europe, US-based drug sponsors indicate that up to 50 per cent of studies are now conducted outside of the US and expect that figure to increase to 65 per cent within three years (1). In 1990, clinical trials were conducted in about 28 countries worldwide. In September 2009, the FDA was regulating 78,276 trials in 172 countries, and the European Medicines Agency (EMEA) expects the trend to conduct more clinical trials in developing nations to increase in years to come.

There are a number of reasons for this shift. Lower costs, access to large numbers of treatment-naïve patients, the potential for fast patient recruitment and the opportunity to expand their presence in emerging markets are among the top reasons pharmaceutical companies are now conducting trials in developing nations. South-east Asia is an increasingly popular destination because it offers all of these benefits.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gary Muddyman is the Managing Director and CEO of Conversis, a leading provider of globalisation, internationalisation, localisation and translation services, specialising in the life sciences sector. Gary started Conversis back in 2003 with the intention of advancing the understanding and use of localisation and translation as a strategic business tool. Before that, he spent 16 years at HSBC.
spacer
Garry Muddyman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI MEA expert:growing domestic manufacturing is creating new opportunities for international Pharma in the Middle East

Abu Dhabi, 5th August 2019: CPhI Middle East expert Emad Shabbir, Director at EMAD Trade House, states favorable conditions and legislative regulations in Saudi Arabia are resulting in a boom of manufacturers and CMOs partnerships with international pharma companies. With the strategic cooperation between regional generic companies and multinational pharma companies, driving increased local production.
More info >>

White Papers

Nasal Drug Delivery with a Focus on Chronic Rhino-Sinusitis

Aptar Pharma

Aptar Pharma have hosted a scientific roundtable on “Nasal drug delivery with a focus on chronic rhino‑sinusitis”. This international scientific forum was held in Paris, France on November 13th 2012. The roundtable was organized to explore and exchange views on the science of various forms of sinusitis and its related unmet medical needs.
More info >>

 
Industry Events

SCOPE Europe – Summit for Clinical Ops Executives Europe

17-18 September 2019, Barcelona, Spain

Building on the success of its long-running US-based counterpart, Summit for Clinical Trials Operations Executives Europe (SCOPE Europe) is a two-day event serving clinical innovation leaders, clin ops execs, functional heads, category managers, and those responsible for the planning and management of clinical trials in Europe and the Rest of the World. The event will feature opening and closing plenary keynote sessions, five conference tracks, interactive breakout discussion groups, and networking. It is an opportunity for leaders from large, mid-sized, and small pharma, specialty pharma, biotech, vendor companies, and academic research centers to come together to share best practices and discuss the new era of analytics-driven and patient-centric trials.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement